Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis - PubMed (original) (raw)
Review
. 2017 Aug;137(8):1646-1654.
doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.
Zenas Z N Yiu 2, Victoria Ward 3, Lesley S Exton 4, M Firouz Mohd Mustapa 4, Eleanor Samarasekera 5, A David Burden 6, Ruth Murphy 7, Caroline M Owen 8, Richard Parslew 9, Vanessa Venning 10, Richard B Warren 2, Catherine H Smith 11
Affiliations
- PMID: 28457908
- PMCID: PMC5519491
- DOI: 10.1016/j.jid.2017.04.009
Review
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
Zarif K Jabbar-Lopez et al. J Invest Dermatol. 2017 Aug.
Erratum in
- Corrigenda.
[No authors listed] [No authors listed] J Invest Dermatol. 2021 Feb;141(2):463. doi: 10.1016/j.jid.2020.12.010. J Invest Dermatol. 2021. PMID: 33504440 Free PMC article. No abstract available.
Abstract
Multiple biologic treatments are licensed for psoriasis. The lack of head-to-head randomized controlled trials makes choosing between them difficult for patients, clinicians, and guideline developers. To establish their relative efficacy and tolerability, we searched MEDLINE, PubMed, Embase, and Cochrane for randomized controlled trials of licensed biologic treatments for skin psoriasis. We performed a network meta-analysis to identify direct and indirect evidence comparing biologics with one another, methotrexate, or placebo. We combined this with hierarchical cluster analysis to consider multiple outcomes related to efficacy and tolerability in combination for each treatment. Study quality, heterogeneity, and inconsistency were evaluated. Direct comparisons from 41 randomized controlled trials (20,561 participants) were included. All included biologics were efficacious compared with placebo or methotrexate at 3-4 months. Overall, cluster analysis showed adalimumab, secukinumab, and ustekinumab were comparable in terms of high efficacy and tolerability. Ixekizumab and infliximab were differentiated by very high efficacy but poorer tolerability. The lack of longer term controlled data limited our analysis to short-term outcomes. Trial performance may not equate to real-world performance, and so results need to be considered alongside real-world, long-term safety and effectiveness data. These data suggest that it is possible to discriminate between biologics to inform clinical practice and decision making (PROSPERO 2015:CRD42015017538).
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
Figure 1
Flow diagram showing the identification of literature in the PRISMA format. RCT, randomized controlled trial.
Figure 2
Network maps for the main outcomes considered in the review. (a) Clear/nearly clear (minimal residual activity/PASI > 90/0 or 1 on PGA). (b) Mean change in the dermatology life quality index. (c) Withdrawal due to adverse events, all at 12 to 16 weeks. Nodes and edges are weighted according to number of studies including that treatment or comparison. ADA, adalimumab; ETA, etanercept; INF, infliximab; IXE, ixekizumab; MTX, methotrexate; PASI, psoriasis area and severity index; PBO, placebo; PGA, physician’s global assessment; SEC, secukinumab; UST, ustekinumab.
Figure 3
Plot of joint rankings based on hierarchical clustering of the surface under the cumulative ranking curve (SUCRA) estimates. Combined estimates of efficacy (clear/nearly clear—minimal residual activity/PASI > 90/0 or 1 on PGA) and tolerability (withdrawal due to adverse events) at 12 to 16 weeks. ADA, adalimumab; ETA, etanercept; INF, infliximab; IXE, ixekizumab; MTX, methotrexate; PASI, psoriasis area and severity index; PBO, placebo; PGA, physician’s global assessment; SEC, secukinumab; UST, ustekinumab.
Comment in
- Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis".
Reich K, Leonardi C, Papp K, Gottlieb A, Thaçi D, Schacht A, Ball S, Agada N, Mallbris L. Reich K, et al. J Invest Dermatol. 2017 Dec;137(12):2642-2644. doi: 10.1016/j.jid.2017.06.031. Epub 2017 Aug 2. J Invest Dermatol. 2017. PMID: 28780085 No abstract available. - Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis.
Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mohd Mustapa MF, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH. Jabbar-Lopez ZK, et al. J Invest Dermatol. 2017 Dec;137(12):2644-2646. doi: 10.1016/j.jid.2017.07.848. Epub 2017 Aug 31. J Invest Dermatol. 2017. PMID: 28864078 No abstract available. - Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis-Correction.
Smith CH, Mahil SK, Yiu ZZN, Bale T, Burden AD, Coates LC, McGuire A, Murphy R, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF. Smith CH, et al. J Invest Dermatol. 2021 Jan;141(1):177-181. doi: 10.1016/j.jid.2020.02.048. J Invest Dermatol. 2021. PMID: 33342507 No abstract available.
Similar articles
- Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH. Mahil SK, et al. Br J Dermatol. 2020 Oct;183(4):638-649. doi: 10.1111/bjd.19325. Epub 2020 Aug 9. Br J Dermatol. 2020. PMID: 32562551 Review. - Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A. Johansson EC, et al. J Med Econ. 2018 Aug;21(8):810-820. doi: 10.1080/13696998.2018.1474747. Epub 2018 Jun 6. J Med Econ. 2018. PMID: 29873270 - Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K, Burden AD, Eaton JN, Hawkins NS. Reich K, et al. Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11. Br J Dermatol. 2012. PMID: 21910698 Review. - Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB. Sawyer LM, et al. J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31. J Eur Acad Dermatol Venereol. 2019. PMID: 30289198 Free PMC article.
Cited by
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis.
Greenzaid J, Feldman S. Greenzaid J, et al. Clin Pharmacokinet. 2024 Feb;63(2):137-153. doi: 10.1007/s40262-023-01341-4. Epub 2024 Jan 27. Clin Pharmacokinet. 2024. PMID: 38280146 Review. - A bibliometrics study on the status quo and hot topics of pathogenesis of psoriasis based on Web of Science.
Yang Y, Zheng X, Lv H, Tang B, Bi Y, Luo Q, Yao D, Chen H, Lu C. Yang Y, et al. Skin Res Technol. 2024 Jan;30(1):e13538. doi: 10.1111/srt.13538. Skin Res Technol. 2024. PMID: 38174774 Free PMC article. - Biologics and Biosimilars in Psoriasis.
Ahmed SS, De A, Das S, Manchanda Y. Ahmed SS, et al. Indian J Dermatol. 2023 May-Jun;68(3):282-295. doi: 10.4103/ijd.ijd_421_23. Indian J Dermatol. 2023. PMID: 37529455 Free PMC article. - Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review.
Nast A, Dressler C, Schuster C, Saure D, Augustin M, Reich K. Nast A, et al. Skin Health Dis. 2022 Apr 23;3(1):e112. doi: 10.1002/ski2.112. eCollection 2023 Feb. Skin Health Dis. 2022. PMID: 36751312 Free PMC article. Review. - Monitoring the effect of TNF-alpha inhibitors on laboratory parameters and adverse effects in different diseases: a retrospective, single-center study.
Madani AN, Al-Saif FM, Alzamil LR, Almazroua AM, Alfurayh NA, Aldokhayel SD, Almuhaideb QA, Alballa NS, Daham NA, Alkharashi AA. Madani AN, et al. Ann Saudi Med. 2022 Sep-Oct;42(5):309-318. doi: 10.5144/0256-4947.2022.309. Epub 2022 Oct 6. Ann Saudi Med. 2022. PMID: 36252145 Free PMC article.
References
- Bansback N., Sizto S., Sun H.Y., Feldman S., Willian M.K., Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009;219:209–218. - PubMed
- Barker J., Hoffmann M., Wozel G., Ortonne J.P., Zheng H., van Hoogstraten H. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) Br J Dermatol. 2011;165:1109–1117. - PubMed
- Basra M.K., Salek M.S., Camilleri L., Sturkey R., Finlay A.Y. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230:27–33. - PubMed
- Bucher H.C., Guyatt G.H., Griffith L.E., Walter S.D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–691. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical